GlaxoSmithKline Pharmaceuticals Limited (IN:GLAXO)
:GLAXO
Want to see IN:GLAXO full AI Analyst Report?
GLAXO Stock Chart & Stats
₹2483.35
-₹2.55(-0.12%)
At close: 4:00 PM EST
₹2483.35
-₹2.55(-0.12%)
Day’s Range― - ―
52-Week Range₹2,218.00 - ₹3,515.95
Previous CloseN/A
Volume25.42K
Average Volume (3M)1.83K
Market Cap
₹418.95B
Enterprise Value₹406.09B
Total Cash (Recent Filing)₹20.61B
Total Debt (Recent Filing)₹357.10M
Price to Earnings (P/E)35.4
Beta0.70
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.16%
Share Statistics
EPS (TTM)16.70
Shares Outstanding169,406,040
10 Day Avg. Volume1,472
30 Day Avg. Volume1,831
Financial Highlights & Ratios
PEG Ratio0.89
Price to Book (P/B)24.29
Price to Sales (P/S)12.72
P/FCF Ratio37.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)69.68
Revenue Forecast (FY)₹42.69B
Bulls Say, Bears Say
Bulls Say
Very Low Financial LeverageA Debt-to-Equity of 0.005 signals almost no financial leverage, giving the company durable financial flexibility. This reduces refinancing risk, supports sustained R&D and capex spending, and preserves optionality for strategic M&A or buffering regulatory pricing pressure over months.
High And Sustainable MarginsElevated gross and net margins indicate durable pricing power and operational efficiency in core pharmaceutical activities. These margins support reinvestment in pipelines, stable EBITDA generation and resilience to cost shocks, underpinning longer-term profitability and cash reinvestment capacity.
Strong Cash GenerationVery strong free cash flow growth and an operating cash flow to net income >1 imply high-quality earnings and significant cash conversion. This durable cash generation funds dividends, R&D, and local manufacturing investments while lowering reliance on external financing over the medium term.
Bears Say
Inconsistent Revenue Growth SignalsA low short-term revenue growth metric versus higher annual figures suggests variability in top-line momentum. This inconsistency can complicate forecasting, reduce visibility into product-level trends, and increase the risk that shortfalls in key products or tenders materially affect medium-term revenue streams.
Opaque Product/segment DisclosureLack of disclosed product and segment detail reduces transparency on revenue diversification and pipeline health. For investors this increases concentration and execution risk because it’s harder to assess dependency on flagship drugs, upcoming expiries, or the sustainability of specific therapeutic revenue.
Exposure To Pricing Controls And Tender RiskSignificant reliance on tender-based sales and markets with pricing controls creates durable margin and revenue pressure risk. Public procurement cycles and government price-setting can compress returns and create lumpy demand, reducing predictability of revenue and margins over the medium term.
GlaxoSmithKline Pharmaceuticals Limited News
GLAXO FAQ
What was GlaxoSmithKline Pharmaceuticals Limited’s price range in the past 12 months?
GlaxoSmithKline Pharmaceuticals Limited lowest stock price was ₹2218.00 and its highest was ₹3515.95 in the past 12 months.
What is GlaxoSmithKline Pharmaceuticals Limited’s market cap?
GlaxoSmithKline Pharmaceuticals Limited’s market cap is ₹418.95B.
When is GlaxoSmithKline Pharmaceuticals Limited’s upcoming earnings report date?
GlaxoSmithKline Pharmaceuticals Limited’s upcoming earnings report date is May 19, 2026 which is in 21 days.
How were GlaxoSmithKline Pharmaceuticals Limited’s earnings last quarter?
GlaxoSmithKline Pharmaceuticals Limited released its earnings results on Feb 09, 2026. The company reported ₹16.7 earnings per share for the quarter, the consensus estimate of ₹16.7 by ₹0.
Is GlaxoSmithKline Pharmaceuticals Limited overvalued?
According to Wall Street analysts GlaxoSmithKline Pharmaceuticals Limited’s price is currently Overvalued.
Does GlaxoSmithKline Pharmaceuticals Limited pay dividends?
GlaxoSmithKline Pharmaceuticals Limited pays a Annually dividend of ₹42 which represents an annual dividend yield of 2.16%. See more information on GlaxoSmithKline Pharmaceuticals Limited dividends here
What is GlaxoSmithKline Pharmaceuticals Limited’s EPS estimate?
GlaxoSmithKline Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GlaxoSmithKline Pharmaceuticals Limited have?
GlaxoSmithKline Pharmaceuticals Limited has 169,406,040 shares outstanding.
What happened to GlaxoSmithKline Pharmaceuticals Limited’s price movement after its last earnings report?
GlaxoSmithKline Pharmaceuticals Limited reported an EPS of ₹16.7 in its last earnings report, expectations of ₹16.7. Following the earnings report the stock price went up 1.012%.
Which hedge fund is a major shareholder of GlaxoSmithKline Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:GLAXO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for anti-infective, respiratory, dermatology, nutrition, gastrointestinal, and rare diseases; and consumer healthcare products. It provides its product under the Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact, Tenovate, Flutivate, Physiogel, Zimig, Cobadex CZS, Infanrix Hexa, Synflorix, Supacef, Havrix, Menveo, Boostrix, Fluarix Tetra, Varilrix, Nucala, and Trelegy Ellipta brands. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.
Technical Analysis
Cipla Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Lupin Limited
―
Sun Pharmaceutical Industries Limited
―
Torrent Pharmaceuticals Ltd
―